FDA Approves New Dose Tablet For Plavix

Armen Hareyan's picture

May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients

Sanofi-aventis and Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for a 300mg tablet of the antiplatelet PLAVIX

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.